Navigation Links
Neuraltus Pharmaceuticals Awarded $733,437 Under the Qualifying Therapeutic Discovery Projects Grant Program (QTDP)
Date:11/5/2010

PALO ALTO, Calif., Nov. 5, 2010 /PRNewswire/ -- Neuraltus Pharmaceuticals, a privately held biopharmaceutical company dedicated to developing and commercializing high-impact therapeutics that address critical unmet needs, primarily in the treatment of neurodegenerative diseases, announced today the Company was awarded three grants totaling $733,437 under the Qualifying Therapeutic Discovery Projects Grant Program (QTDP).  The grants are being provided under section 48D of the Internal Revenue Code, enacted as part of the Patient Protection and Affordable Care Act of 2010.  The grants will be used to advance Neuraltus' product pipeline, including NP001, NP002 and NP003.  

Neuraltus currently is evaluating NP001 for the treatment of Amyotrophic Lateral Sclerosis (ALS, or Lou Gehrig's disease) in an ongoing Phase 1 study. NP001 is a novel small molecule that regulates macrophage activation, with potential application to a number of neurodegenerative diseases, including ALS, Alzheimer's disease, Parkinson's disease and multiple sclerosis.  NP002, Neuraltus' small molecule, nicotinic receptor agonist currently is in a Phase 1/2 study for L-dopa-induced dyskinesias (muscle movement disorders), a primary side effect of L-dopa treatment in Parkinson's disease patients.  In addition, Neuraltus is developing NP003, an orally bioavailable, small molecule designed to treat lysosomal storage disorders such as Fabry's disease and Gaucher's disease, as well as Parkinson's disease.

Andrew Gengos, Neuraltus' President and CEO, commented, "We are very pleased to receive this grant.  There remain significant unmet needs in the treatment of neurodegenerative diseases, specifically, ALS, Alzheimer's disease and Parkinson's disease.  Each of Neuraltus' programs represents a first-in-class approach to treating these indications.  With the help of the QTDP grant, Neuraltus will be able to further develop NP001, NP002 and NP003
'/>"/>

SOURCE Neuraltus Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/17/2014)... Oct. 17, 2014 With the recent ... function has come across several challenges in creating ... managing globalization.  The Medical ... dedicated to providing benchmarking and best practices across ... is a service composed of three stages: 1) ...
(Date:10/17/2014)... , Oct. 17, 2014  Hanger, Inc. (NYSE: ... to report its results of operations for the quarter ... after the market closes.  A conference call to discuss ... ET, on Friday, November 7, 2014. Those wishing to ... until Friday, November 14, 2014 by dialing 1-855-859-2056 and ...
(Date:10/17/2014)... NORWALK, Conn. , Oct. 17, 2014 UBM ... , a leading online community and information resource for ... Parkinson disease and Alzheimer disease , with discussions ... Up to 1 million Americans have Parkinson disease , ... muscular dystrophy, or Lou Gehrig disease. Diagnosis can ...
Breaking Medicine Technology:Early Key Findings from the Medical Affairs Consortium Research 2Neurology Times Features Coverage of Parkinson and Alzheimer Disease 2Neurology Times Features Coverage of Parkinson and Alzheimer Disease 3
... ROSA, Calif., Feb. 14, 2011 / PRNewswire/ ... closed a $22 million Series D financing round led ... round were Split Rock Partners, Legacy Life Sciences, EDF ... and Asset Management Partners.  In connection with the financing, ...
... (Nasdaq: DYNT ) today announced results for its ... for the quarter ended December 31, 2010, were $8,199,347, compared ... for the six months ended December 31, 2010, were $16,118,635, ... year. Net income for the quarter ended ...
Cached Medicine Technology:Sonoma Orthopedic Products® Closes $22 Million Series D Financing 2Dynatronics Announces Fiscal Second Quarter Results 2Dynatronics Announces Fiscal Second Quarter Results 3Dynatronics Announces Fiscal Second Quarter Results 4
(Date:10/20/2014)... California (PRWEB) October 20, 2014 Final Cut ... the release of the Citrus theme for FCPX filmmakers ... would use to describe the Citrus theme” Says Christina Austin, ... easy to look so professional.” , Citrus comes with all ... with the template are: four transitions for added style, a ...
(Date:10/20/2014)... 2014 It’s hard to imagine what it’s ... vulnerable children around the world, it’s a reality. And while ... children are forced to walk barefoot on rocky terrain or ... play with their friends. , Buckner International's Shoes ... Radio in October to encourage support for Air1 and ...
(Date:10/20/2014)... Houston plastic surgeon Dr. Christopher Patronella ... innovative True Form Tummy Tuck® method as ... at The University of Texas Medical Branch in ... medical student. Patronella, who is a founding partner of ... in Texas, The Aesthetic Center for Plastic Surgery ...
(Date:10/19/2014)... Hastings and Hastings, a Phoenix personal ... throughout the greater Phoenix area and across Arizona reports ... to catastrophic automobile accidents. Statistics have indicated a steady ... Arizona. As such, Hastings and Hastings has seen a ... those who have been injured through no fault of ...
(Date:10/19/2014)... October 20, 2014 Recently, BambooIndustry.com, one ... unveiled its new range of bamboo deckings . ... these natural items; they are now available at deeply ... people, it is hard to overstate the significance of ... attention to online services. The company’s workers are striving ...
Breaking Medicine News(10 mins):Health News:Today Pixel Film Studios Announced the Release of the Citrus theme for Final Cut Pro X 2Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 2Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 3Health News:Plastic Surgeon Patronella Presents Artistically-Inspired Tummy Tuck Method to Future Generation of Plastic Surgeons in Texas 2Health News:Hastings And Hastings Reports Record Demand In 2014 For Legal Representation With Regard To Catastrophic Automobile Accidents 2Health News:Hastings And Hastings Reports Record Demand In 2014 For Legal Representation With Regard To Catastrophic Automobile Accidents 3Health News:High Quality Bamboo Deckings, New Items Unveiled By BambooIndustry.com 2
... in a loss would have to pay the private sector up ... position // to fulfil the commitment to supply staff to help ... ,The trusts in the south of England were expected to second ... deal with Japanese firm Fujitsu. But the health Department has confirmed ...
... private sector employees, NHS staff take more leave per year’. ... says, about 12 days (4.5% of working days) per year seems ... in NHS. ,Bosses' organisation NHS Employers sick leave corresponds ... have planned to reduce long-term absence by launching a drive on ...
... three residents at a Eastercroft nursing home in Caldercruix, ... braced itself for possible further cases of tuberculosis after the ... ,While two of the victims died in ‘early May’ the ... resident has been reported to be recovering after being diagnosed ...
... for Health Information has found that although men experience more heart ... fatal. The study also found that women are at an increased ... the first time we know there's a difference. Now we have ... Zelmer, vice president of research and analysis for the Canadian Institute ...
... Dr. Robert Thwala, the Ministry of Agriculture Director of ... the African Regional Commission //for the International Committee of ... ,Dr. Barry O’Neil was earlier elected the President of ... elections were held last month during the 74th Annual ...
... they are forced into taking treatment elsewhere and that causes them a ... Ulster man, who had to pay thousands of pounds so that he ... the waiting list was too long to wait for. He had to ... rheumatoid arthritis. The bad part is none of them has been successful. ...
Cached Medicine News:Health News:Already Short Staffed And In Deficit NHS Fails To Supply Staff For IT Project 2
Blunt tipped forceps with a smooth, pliable silicone coating on the entire interior surface of the tip. For removal of foreign bodies or atraumatic tissue grasping....
Blunt tipped forceps with small, slightly pointed grasping platforms on each tip. For general purpose (fine) membrane grasping and grasping membranes adherent to the retlnal surface....
... and 384-well plates and strips with ... a self contained and programmable instrument, ... of precise fluidic delivery from the ... bottle to the full force of ...
... The D.O.R.C. Intraocular Electromagnet offers a truly ... ferrous intraocular foreign bodies (IOFB). Other magnets ... D.O.R.C. offers an intraocular electromagnet for use ... sky surgical technique. The D.O.R.C. Intraocular Electromagnet ...
Medicine Products: